論文

国際誌
2022年3月17日

Outcome of therapy-related myelodysplastic syndrome and oligoblastic acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A propensity score matched analysis.

Hematological oncology
  • Hidehiro Itonaga
  • Michiko Kida
  • Atsushi Hamamura
  • Naoyuki Uchida
  • Yukiyasu Ozawa
  • Takahiro Fukuda
  • Yasunori Ueda
  • Keisuke Kataoka
  • Yuta Katayama
  • Shuichi Ota
  • Ken-Ichi Matsuoka
  • Tadakazu Kondo
  • Tetsuya Eto
  • Junya Kanda
  • Tatsuo Ichinohe
  • Yoshiko Atsuta
  • Yasushi Miyazaki
  • Ken Ishiyama
  • 全て表示

40
4
開始ページ
752
終了ページ
762
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1002/hon.2991

Therapy-related myelodysplastic syndromes (t-MDS) are generally progressive and associated with poorer outcomes than de novo MDS (d-MDS). To evaluate the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for t-MDS, we conducted a propensity score matched-pair analysis of patients with t-MDS and d-MDS using a nationwide database. A total of 178 patients with t-MDS underwent allo-HSCT between 2001 and 2018, and 178 out of 3123 patients with d-MDS were selected. The probability of 3-year overall survival rate was 40.0% and 50.0% in the t-MDS and d-MDS groups, respectively (p = 0.032). The 3-year transplant-related mortality was 30.9% and 19.0% in the t-MDS and d-MDS groups, respectively (p = 0.005). The 3-year cumulative incidence of relapse was 32.8% and 33.0% in the t-MDS and d-MDS groups, respectively (p = 0.983). A multivariate analysis identified four adverse factors for overall survival in the t-MDS group: age ≥ 55 years (hazard ratio [HR], 2.09; 95% CI, 1.11-3.94; p = 0.023), the poor cytogenetic risk group (HR, 2.19; 95% CI, 1.40-4.19; p = 0.019), performance status at allo-HSCT 2-4 (HR, 2.14; 95% CI, 1.19-3.86; p = 0.011), and a shorter interval from diagnosis to transplantation (<8 months; HR, 1.61; 95% CI, 1.00-2.57; p = 0.048). The most frequent cause of transplant-related death was the infectious complications (21.6%) in t-MDS group and organ failure (12.5%) in d-MDS group. In conclusion, allo-HSCT potentially provides long-term remission in patients with t-MDS; however, further efforts to reduce transplant-related death are needed.

リンク情報
DOI
https://doi.org/10.1002/hon.2991
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/35299289
ID情報
  • DOI : 10.1002/hon.2991
  • PubMed ID : 35299289

エクスポート
BibTeX RIS